DEA Bans N-Pyrrolidino What? Two New Drugs Hit Schedule I
Published Date: 1/12/2026
Rule
Summary
Starting February 11, 2026, two powerful new drugs—N-pyrrolidino metonitazene and N-pyrrolidino protonitazene—are officially banned and placed in the strictest drug category, Schedule I. This means anyone making, selling, or using these drugs faces serious legal trouble. The move helps the U.S. follow international drug rules and keeps communities safer without adding new costs.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Two Nitazenes Permanently Banned
Starting February 11, 2026, N-pyrrolidino metonitazene and N-pyrrolidino protonitazene are permanently placed in Schedule I. Anyone who makes, sells, imports, exports, researches, or possesses these drugs without DEA authorization is subject to the Controlled Substances Act's administrative, civil, and criminal sanctions.
Retail Sales and Unauthorized Possession Prohibited
Retail sales of Schedule I controlled substances to the general public are not allowed, and possession of any quantity of these substances without authorization under the CSA is unlawful. Persons in unauthorized possession may be prosecuted under the Controlled Substances Act.
DEA Registration and Compliance Required
If you handle these substances for any lawful purpose, you must be registered with DEA and follow Schedule I rules. That includes registration under 21 U.S.C. 822/823, disposal under 21 CFR part 1317, Schedule I security rules (21 CFR 1301.71–1301.76), labeling/packaging requirements, manufacturing quotas, initial inventory and biennial inventories, records and reports (including Automated Reports and Consolidated Order System reporting), and order form and import/export rules.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-00357 — Airworthiness Directives; Baykar Piaggio Aerospace S.p.A. (Type Certificate Previously Held by Piaggio Aviation S.p.A.) Airplanes
If you own or operate a Baykar Piaggio P-180 airplane, listen up! The FAA found leaks in some flexible hydraulic hoses and now requires you to replace them by February 17, 2026. Plus, you can’t install those old hoses anymore—keeping your plane safe and sound without breaking the bank.
Next: 2026-00392 — Atlantic Highly Migratory Species; Atlantic Bluefin Tuna Fisheries; General Category January Through March Quota Transfer
NOAA is shifting 26 metric tons of Atlantic bluefin tuna quota from December 2026 to January through March 2026 to give commercial fishermen more chances to catch tuna early in the year. This change affects fishermen with General category and Charter/Headboat permits who sell their catch commercially. The new quota rules kick in on January 8, 2026, and last through March 31, 2026.